查看購物車
  • Japanese
封面
市場調查報告書
商品編碼
1998487

全球體外診斷試劑盒市場：呼吸系統/非呼吸系統（2020-2030 年）

Worldwide IVD Panel-Based Testing: Respiratory/Non-Respiratory, 2020-2030
出版日期: | 出版商: Kalorama Information | 英文 133 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球呼吸道和非呼吸道體外診斷（IVD）檢測組合市場正經歷持續的結構性變化。檢測組合能夠從單一檢體同時檢測多種病原體和抗藥性標記物，提高工作流程效率、縮短檢測時間並提升診斷可靠性。市場成長日益受到臨床應用和各種檢測環境中使用量增加的推動。

Kalorama Information 在其報告《全球 IVD 偵測板市場 - 呼吸系統/非呼吸系統（2020-2030年）》中提供了該市場的分析、估算和預測。

細分市場概覽

呼吸道疾病檢測組合仍然是檢測組合市場的重要組成部分，這得益於其廣泛的臨床應用和持續的季節性需求。這些檢測以多種形式提供，包括分子診斷、免疫檢測和照護現場（POC）平台，並佔據了整體市場收入的相當大佔有率。

非呼吸道疾病檢測組合在檢測計畫中佔比不斷成長，並廣泛應用於感染疾病和其他專業檢測領域。這個細分市場反映了檢測計畫日益多樣化以及基於檢測組合的方法在多個檢查室環境中的整合應用。

最終用戶和醫療保健專業人員

對綜合檢測的需求主要集中在醫院和急診機構，因為這些機構需要進行多種檢測並快速做出臨床決策。急診和重症監護室的檢測量佔絕大多數，但其他醫療機構也存在非呼吸系統疾病的檢測需求。

地理範圍

北美地區擁有成熟的市場基礎和完善的診斷基礎設施，是呼吸系統和非呼吸系統體外診斷試劑盒檢測的最大區域市場。 《2020-2030年全球體外診斷試劑盒檢測 - 呼吸系統/非呼吸系統》報告也分析了歐洲、亞太地區和世界其他地區，提供了全球市場展望。

調查方法

本報告從製造商層級分析了全球體外診斷試劑盒市場，涵蓋了多個技術類別的呼吸系統和非呼吸系統檢測。

  • 分子
  • 免疫檢測
  • 照護端
  • 核心檢查室
  • 組織病理學
  • 免疫血液學

市場資料涵蓋2020年至2030年，以2025年為基準年，並計算了2025年至2030年預測期的年複合成長率（CAGR）。報告包含區域和終端用戶分析，預測基於人口趨勢、技術創新、新產品開發和全球擴張。

研究結果是基於廣泛的一手和二手資料研究，包括對行業高管、顧問、醫療保健專業人員和政府相關人員的採訪，並得到了對公司文件、資料庫、投資報告以及醫學和商業期刊的分析的支持。

目錄

第1章 執行摘要

第2章 引言

  • 概述
  • 體外診斷（IVD）臨床檢測組的類型
    • 感染疾病檢測組
    • 專門針對感染疾病的小型檢測小組
    • 抗菌素抗藥性（AMR）檢測組
    • 腫瘤基因組（NGS）檢測組
    • STI試劑盒
    • 基因和遺傳疾病檢測
    • 產前檢測項目
    • 挑戰與趨勢
    • 多重檢測費用償付
    • 體外診斷多重檢測法規概述
    • 多重體外診斷檢測的優勢
    • 臨床意義及過度檢查的挑戰

第3章 分子體外診斷試劑盒檢測

  • 介紹
  • 終端用戶市場：分子體外診斷試劑盒
  • 呼吸技術檢測組
    • 分子呼吸系統體外診斷試劑盒檢測
    • 呼吸系統臨床適應小組
    • 症狀性性行為感染呼吸道病原體檢測
    • 針對特定族群的迷你和組合呼吸道檢測板
    • 實驗室分子檢測板市場
  • 非呼吸系統技術檢測組
    • 分子感染疾病（非呼吸系統）多重檢測
    • 血流
    • 性行為感染感染（STI）
    • 肝炎
    • 驗血
    • 其他
    • 分子檢測及其他非呼吸道疾病檢測
    • 腫瘤學
    • 基因
    • 組織類型鑑定
    • 區域市場概覽

第4章 體外免疫檢測組合

  • 介紹
  • 終端用戶市場：免疫檢測體外診斷試劑盒
  • 呼吸技術檢測組
    • 免疫檢測組合板
  • 非呼吸系統技術檢測組
    • 採用免疫檢測法進行非呼吸道感染疾病多重檢測
    • 血流
    • 性行為感染感染（STI）
    • 肝炎
    • ToRCH
    • 血庫篩檢
    • 用於體外診斷其他非呼吸系統疾病的多重免疫檢測法檢測
    • 過敏
    • 自體免疫
    • 甲狀腺
    • 藥物毒理學與濫用
    • 其他免疫檢測組（不包括呼吸系統）
    • 區域市場概覽

第5章 照護現場（POC）體外診斷試劑盒檢查

  • 介紹
  • 終端用戶市場：照護現場試劑盒
  • 呼吸技術檢測組
    • 即時免疫檢測組
    • 即時分子呼吸道檢測板
  • 非呼吸系統技術檢測組
    • 照護現場（POC）非呼吸道感染疾病檢測
    • 性行為感染傳染病
    • 肝炎
    • 其他感染疾病
    • 照護現場（POC）非呼吸系統及其他體外診斷試劑盒檢測
    • 重症監護
    • 血液學
    • 脂質
    • 毒理學/藥物濫用
    • 尿液檢查
    • 其他
  • 區域市場概覽

第6章 核心實驗室小組檢查

  • 介紹
  • 終端用戶市場：CoreLab IVD 試劑盒
  • 普通化學體外診斷試劑盒檢測
  • 血液氣體外診斷試劑盒檢測
  • 尿液檢查IVD 檢測
  • 血液學體外診斷試劑盒檢測
  • 區域市場概覽

第7章 解剖病理學檢查

  • 介紹
  • 終端用戶市場：解剖病理學體外診斷試劑盒
  • 區域市場概覽

第8章 免疫血液學檢測

  • 介紹
  • 終端用戶市場：免疫血液學體外診斷試劑盒
  • 區域市場概覽

第9章 體外診斷（IVD）檢測的市場小組分析

  • 整體市場
    • 呼吸系統體外診斷試劑盒市場
    • 非呼吸道病原體檢測板體外診斷檢測市場
  • 目標市場
    • 呼吸系統
    • 感染疾病（非呼吸道）
    • 血液感染疾病/院內感染/敗血症
    • 性行為感染傳染病
    • 肝炎
    • 血庫篩檢
    • ToRCH
    • 其他（非呼吸系統）體外診斷測試組也包含在內。
  • 依最終用戶分類的市場分佈
    • 醫院檢查室
    • 急診（ER）/緊急護理室（UC）
    • 獨立/參考測試機構
    • 診所
    • 非處方藥/零售/其他
  • 區域市場
    • 北美洲
    • 歐洲
    • 亞太地區
    • 其他地區
簡介目錄
Product Code: 26-033KA

The global market for respiratory and non-respiratory IVD panel-based testing is undergoing continued structural evolution. Panel-based tests allow for the simultaneous detection of multiple pathogens and or resistance markers from a single specimen, supporting efficient workflows, faster time to results, and greater diagnostic confidence. Market growth is increasingly driven by broader clinical adoption and expanding use across a range of testing environments.

Kalorama Information analyzes, estimates, and forecasts this market in Worldwide IVD Panel-Based Testing: Respiratory/Non-Respiratory, 2020-2030.

Segment Landscape

Respiratory panels remain an important component of the panel-based testing market, supported by widespread clinical use and recurring seasonal demand. These tests are offered across multiple formats, including molecular, immunoassay, and point-of-care platforms, and represent a meaningful share of overall market revenues.

Non-respiratory panels account for a growing portion of panel-based testing and span a range of applications, including infectious disease and other specialized testing areas. This segment reflects increasing test menu diversity and the integration of panel-based approaches across multiple laboratory settings.

End Users and Care Settings

Demand for panel-based testing is concentrated in hospital and acute care environments, where broad test menus and rapid clinical decision-making are essential. Emergency and urgent care settings contribute significant testing volumes, while additional utilization occurs across other care settings for non-respiratory applications.

Geographic Scope

North America is the largest regional market for respiratory and non-respiratory IVD panel-based testing, supported by a well-established installed base and mature diagnostic infrastructure. Worldwide IVD Panel-Based Testing: Respiratory/Non-Respiratory, 2020-2030 also examines Europe, Asia Pacific, and the Rest of the World to provide a global market perspective.

Scope and Methodology

This report analyzes the global IVD panel-based testing market at the manufacturer level, covering both respiratory and non-respiratory tests across multiple technology categories:

  • Molecular
  • Immunoassay
  • Point-of-care
  • Core laboratory
  • Anatomic pathology
  • Immunohematology

Market data spans 2020 through 2030, with 2025 as the base year and CAGR calculations provided for the 2025 to 2030 forecast period. Regional and end-user analyses are included, with forecasts informed by demographic trends, technological innovation, new product development, and global expansion.

Research findings are based on extensive primary and secondary research, including interviews with industry executives, consultants, healthcare providers, and government personnel, supported by analysis of company materials, databases, investment reports, and medical and business journals.

Table of Contents

Chapter 1: Executive Summary

  • About Kalorama Information
  • Industry at a Glance
  • Scope and Methodology
  • Size and Growth of the Market
    • Table 1-1: Total IVD Panel Market, 2020-2030 ($ million)
    • Figure 1-1: Total IVD Panel Market, 2020-2030 ($ million)
  • Key Issues and Trends Affecting the Market
  • Conclusion Highlights

Chapter 2: Introduction

  • Overview
  • IVD Clinical Panel Types
    • Infectious Disease Syndromic Panels
    • Targeted Infectious Disease Mini-Panels
    • Antimicrobial Resistance (AMR) Panels
    • Oncology Genomic (NGS) Panels
    • STI Panels
    • Genetic and Inherited Disease Panels
    • Prenatal Panels
    • Issues and Trends
    • Reimbursement for Multiplex Tests
    • IVD Multiplex Regulatory Overview
    • Advantages of Multiplex IVD Testing
    • Clinical Relevance and Over-Testing Challenges

Chapter 3: Molecular IVD Panel-Based Tests

  • Introduction
    • Table 3-1: Molecular IVD Panel-Based Tests, Overall Segment Revenue, 2020-2030 ($ million)
    • Figure 3-1: Molecular IVD Panel-Based Tests, Respiratory/Non-Respiratory Revenue, 2020-2030 ($ million)
    • Figure 3-2: Molecular IVD Panel-Based Tests, Respiratory/Non-Respiratory Revenue Distribution, 2025 (%)
  • End User Market: Molecular IVD Panels
    • Figure 3-3: End User Revenue Source Distribution: Molecular IVD Panel-Based Tests, 2025 (%) [Emergency and Acute Care Units, Hospital Laboratories, Independent and Reference Laboratories, Physician Offices]
  • Respiratory Technology Panels
    • Molecular Respiratory IVD Panel-Based Tests
    • Respiratory Clinical Indication Panels
    • Syndromic Infectious Disease Respiratory Panels
    • Targeted Mini and Combo Respiratory Panels
    • Lab-based Molecular Panel Market
      • Table 3-2: Lab-based Molecular Respiratory IVD Panel-Based Tests, 2025-2030 ($ million)
      • Figure 3-4: Lab-based Molecular Respiratory IVD Panel-Based Tests, 2020-2030 ($ million)
      • Figure 3-5: Lab-based Molecular Respiratory IVD Panel-Based Tests, Distribution by Type, 2025 (%) [Syndromic, Combo/Mini]
  • Non-Respiratory Technology Panels
    • Molecular Infectious Disease (Non-Respiratory) Multiplex Panels
      • Table 3-3: Molecular Non-Respiratory Infectious Disease Panel-Based Tests, Overall Market, 2025-2030 ($ million)
      • Figure 3-6: Molecular Non-Respiratory Infectious Disease Panel-Based Tests, by Type, 2020-2030 ($ million) [Blood Bank Screening; Bloodstream Infection, HAI, Sepsis, STI; Hepatitis; Other Infectious Disease]
    • Bloodstream
      • Table 3-4: Molecular Bloodstream Non-Respiratory Infectious Disease Panel-Based Tests, 2025-2030 ($ million)
    • Sexually Transmitted Infections (STI)
      • Table 3-5: Molecular Sexually Transmitted Infection (STI) Non-Respiratory Infectious Disease Panel-Based Tests, 2025-2030 ($ million)
    • Hepatitis
      • Table 3-6: Molecular Hepatitis Non-Respiratory Infectious Disease Panel-Based Tests, 2025-2030 ($ million)
    • Blood Screening
      • Table 3-7: Molecular Blood Screening Non-Respiratory Infectious Disease Panel-Based Tests, 2025-2030 ($ million)
    • Other
      • Table 3-8: Other Molecular Non-Respiratory Infectious Disease Panel-Based Tests, 2025-2030 ($ million)
    • Molecular and Other Non-Respiratory Panel-Based Tests
      • Table 3-9: Molecular and Other Non-Respiratory IVD Panel-Based Tests, Overall Market, 2025-2030 ($ million)
      • Figure 3-7: Molecular and Other Non-Respiratory IVD Panel-Based Tests, 2020-2030 ($ million) [Genetic, Oncology, Tissue Typing]
    • Oncology
      • Table 3-10: Molecular Oncology IVD Panel-Based Tests, 2025-2030 ($ million)
    • Genetic
      • Table 3-11: Molecular Genetic IVD Panel-Based Tests, 2025-2030 ($ million)
    • Tissue Typing
      • Table 3-12: Molecular Tissue Typing IVD Panel-Based Tests, 2025-2030 ($ million)
    • Geographic Market Overview
      • Table 3-13: Regional Summary - Molecular IVD Panels, 2025-2030 ($ million) [Asia Pacific, Europe, North America, RoW]
      • Figure 3-8: Regional Summary - Molecular IVD Panels, 2020-2030 ($ million) [Asia Pacific, Europe, North America, RoW]

Chapter 4: Immunoassay IVD Panel-Based Tests

  • Introduction
    • Table 4-1: Immunoassay IVD Panel-Based Tests, Overall Segment Revenue, 2020-2030 ($ million)
    • Figure 4-1: Immunoassay IVD Panel-Based Tests (Respiratory, Non-Respiratory), 2020-2030 ($ million)
    • Figure 4-2: Immunoassay IVD Panel-Based Tests, Respiratory/Non-Respiratory Revenue Distribution, 2025 (%)
  • End User Market: Immunoassay IVD Panels
    • Figure 4-3: End User Revenue Source Distribution, Immunoassay IVD Panel-Based Tests, 2025 (%) [Emergency and Acute Care Units, Hospital Laboratories, Independent and Reference Laboratories, Physician Offices]
  • Respiratory Technology Panels
    • Immunoassay Combo Panels
      • Table 4-2: Immunoassay Respiratory IVD Panel-Based Tests, 2025-2030 ($ million)
      • Figure 4-4: Immunoassay Respiratory IVD Panel-Based Tests, 2020-2030 ($ million)
  • Non-Respiratory Technology Panels
    • Immunoassay Non-Respiratory Infectious Disease Multiplex Panels
      • Table 4-3: Immunoassay Non-Respiratory Infectious Disease IVD Panel-Based Tests, 2025-2030 ($ million)
      • Figure 4-5: Immunoassay Non-Respiratory Infectious Disease IVD Panel-Based Tests, by Type, 2020-2030 ($ million) [Blood Bank Screening; Bloodstream, HAI, Sepsis; Hepatitis; STI; ToRCH; Other]
    • Bloodstream
      • Table 4-4: Bloodstream Immunoassay Infectious Disease IVD Panel-Based Tests, 2025-2030 ($ million)
    • Sexually Transmitted Infections (STI)
      • Table 4-5: Sexually Transmitted Infections (STI) Immunoassay Infectious Disease IVD Panel-Based Tests, 2025-2030 ($ million)
    • Hepatitis
      • Table 4-6: Hepatitis Immunoassay Infectious Disease IVD Panel-Based Tests, 2025-2030 ($ million)
    • ToRCH
      • Table 4-7: ToRCH Infectious Disease IVD Immunoassay Panel-Based Tests, 2025-2030 ($ million)
    • Blood Bank Screening
      • Table 4-8: Blood Bank Infectious Disease Screening Immunoassay IVD Panel-Based Tests, 2025-2030 ($ million)
    • Immunoassay Other Non-Respiratory Disease IVD Multiplex Panels
      • Table 4-9: Immunoassay and Other Non-Respiratory Disease IVD Multiplex Panel-Based Tests, 2025-2030 ($ million)
    • Allergy
      • Table 4-10: Allergy Immunoassay Panel-Based Tests, 2025-2030 ($ million)
    • Autoimmune
      • Table 4-11: Autoimmune Immunoassay Panel-Based Tests, 2025-2030 ($ million)
    • Thyroid
      • Table 4-12: Thyroid Immunoassay Panel-Based Tests, 2025-2030 ($ million)
    • Toxicology and Drugs of Abuse
      • Table 4-13: Toxicology and Drugs of Abuse Immunoassay Panel-Based Tests, 2025-2030 ($ million)
    • Other Immunoassay Panels (Non-Respiratory)
      • Table 4-14: Other Immunoassay Panel-Based Tests, 2025-2030 ($ million)
      • Figure 4-6: Immunoassay Non-Respiratory Other IVD Panel-Based Tests, by Type, 2020-2030 ($ million) [Allergy, Autoimmune, Thyroid, Toxicology/Drugs of Abuse, Other]
    • Geographic Market Overview
      • Table 4-15: Immunoassay Panel-Based Tests, Geographic Markets, 2025-2030 ($ million) [Asia Pacific, Europe, North America, RoW]
      • Figure 4-7: Regional Summary: Immunoassay IVD Panels, 2020-2030 ($ million) [Asia Pacific, Europe, North America, RoW]

Chapter 5: Point-of-Care (POC) IVD Panel-Based Tests

  • Introduction
    • Table 5-1: POC IVD Panel-Based Tests, Overall Segment Revenue, 2020-2030 ($ million)
    • Figure 5-1: POC IVD Panel-Based Tests, by Segment, 2020-2030 ($ million) [Respiratory, Non-Respiratory]
    • Figure 5-2: POC IVD Panel-Based Tests, Respiratory/Non-Respiratory Revenue Distribution, 2025 (%)
  • End User Market: Point-of-Care IVD Panels
    • Figure 5-3: End User Revenue Source Distribution: POC IVD Panel-Based Tests, 2025 (%) [Emergency and Acute Care Units, Hospital Laboratories, OTC and Retail Settings, Physician Offices]
  • Respiratory Technology Panels
    • POC Immunoassay Respiratory Panels
      • Table 5-2: POC Immunoassay Respiratory Panel-Based Tests, 2025-2030 ($ million)
    • POC Molecular Respiratory Panels
      • Table 5-3: POC Molecular Respiratory Panel-Based Tests, 2025-2030 ($ million)
      • Figure 5-4: POC Respiratory IVD Panel-Based Tests, 2020-2030 ($ million) [Immunoassay/Molecular]
  • Non-Respiratory Technology Panels
    • POC Non-Respiratory Infectious Disease Panel-Based Tests
      • Figure 5-5: POC Non-Respiratory Infectious Disease IVD Panel-Based Tests, 2020-2030 ($ million) [Hepatitis, STI, Other]
    • Sexually Transmitted Infections
      • Table 5-4: POC Sexually Transmitted Infection (STI) Non-Respiratory Infectious Disease IVD Panel-Based Tests, 2025-2030 ($ million)
    • Hepatitis
      • Table 5-5: POC Hepatitis Non-Respiratory Infectious Disease IVD Panel-Based Tests, 2025-2030 ($ million)
    • Other Infectious Diseases
      • Table 5-6: POC Other Infectious Disease IVD Panel-Based Tests, 2025-2030 ($ million)
    • POC Non-Respiratory Other IVD Panel-Based Tests
      • Table 5-7: POC Non-Respiratory Other IVD Panel-Based Tests, 2025-2030 ($ million)
      • Figure 5-6: POC Other Non-Respiratory IVD Panel-Based Tests, 2020-2030 ($ million) [Critical Care, Hematology, Lipid, Tox/Drug of Abuse, Urinalysis, Other]
    • Critical Care
      • Table 5-8: POC Critical Care IVD Panel-Based Tests, 2025-2030 ($ million)
    • Hematology
      • Table 5-9: POC Hematology IVD Panel-Based Tests, 2025-2030 ($ million)
    • Lipid
      • Table 5-10: POC Lipid IVD Panel-Based Tests, 2025-2030 ($ million)
    • Toxicology/Drugs of Abuse
      • Table 5-11: POC Toxicology/Drugs of Abuse IVD Panel-Based Tests, 2025-2030 ($ million)
    • Urinalysis
      • Table 5-12: POC Urinalysis IVD Panel-Based Tests, 2025-2030 ($ million)
    • Other
      • Table 5-13: POC Other IVD Panel-Based Tests, 2025-2030 ($ million)
  • Geographic Market Overview
    • Table 5-14: POC IVD Panels, Geographic Markets, 2025-2030 ($ million) [Asia Pacific, Europe, North America, RoW]
    • Figure 5-7: Regional Summary - POC IVD Panels, 2020-2030 ($ million) [Asia Pacific, Europe, North America, RoW]

Chapter 6: Core Laboratory Panel-Based Tests

  • Introduction
    • Table 6-1: Core Lab IVD Panel-Based Tests, Overall Segment Revenue, 2020-2030 ($ million)
    • Figure 6-1: Core Lab IVD Panel-Based Tests, 2020-2030 ($ million)
  • End User Market: Core Lab IVD Panels
    • Figure 6-2: End User Revenue Source Distribution: Core Lab IVD Panel-Based Tests, 2025 (%) [Emergency and Acute Care Units, Hospital Laboratories, Independent and Reference Laboratories, OTC and Retail Settings, Physician Offices]
  • General Chemistry IVD Panel-Based Tests
    • Table 6-2: General Chemistry IVD Panel-Based Tests, 2020-2030 ($ million)
    • Figure 6-3: General Chemistry IVD Panel Summary, 2020-2030 ($ million)
  • Blood Gases IVD Panel-Based Tests
    • Table 6-3: Blood Gases IVD Panel-Based Tests, 2020-2030 ($ million)
    • Figure 6-4: Blood Gases IVD Panel Summary, 2020-2030 ($ million)
  • Urinalysis IVD Panel-Based Tests
    • Table 6-4: Urinalysis IVD Panel-Based Tests, 2020-2030 ($ million)
    • Figure 6-5: Urinalysis IVD Panel Summary, 2020-2030 ($ million)
  • Hematology IVD Panel-Based Tests
    • Table 6-5: Hematology IVD Panel-Based Tests, 2020-2030 ($ million)
    • Figure 6-6: Hematology IVD Panel Summary, 2020-2030 ($ million)
  • Geographic Market Overview
    • Table 6-6: Core Lab IVD Panels, Geographic Markets, 2025-2030 ($ million) [Asia Pacific, Europe, North America, RoW]
    • Figure 6-7: Regional Summary - Core Lab IVD Panels, 2020-2030 ($ million) [Asia Pacific, Europe, North America, RoW]

Chapter 7: Anatomic Pathology Panel-Based Tests

  • Introduction
    • Table 7-1: Anatomic Pathology IVD Panel-Based Tests, Overall Segment Revenue, 2020-2030 ($ million)
    • Figure 7-1: Anatomic Pathology IVD Panel-Based Tests, 2020-2030 ($ million)
  • End User Market: Anatomic Pathology IVD Panels
    • Figure 7-2: End User Revenue Source Distribution: Anatomic Pathology IVD Panel-Based Tests, 2025 (%) [Emergency and Acute Care Units, Hospital Laboratories, Independent and Reference Laboratories, Physician Offices]
  • Geographic Market Overview
    • Table 7-2: Anatomic Pathology Panel-Based Tests, Geographic Markets, 2025-2030 ($ million) [Asia Pacific, Europe, North America, RoW]
    • Figure 7-3: Regional Summary - Anatomic Pathology IVD Panels, 2020-2030 ($ million) [Asia Pacific, Europe, North America, RoW]

Chapter 8: Immunohematology Panel-Based Tests

  • Introduction
    • Table 8-1: Immunohematology IVD Panel-Based Tests, 2020-2030 ($ million)
    • Figure 8-1: Immunohematology IVD Panel-Based Tests, 2020-2030 ($ million)
  • End User Market: Immunohematology IVD Panels
    • Figure 8-2: End User Revenue Source Distribution: Immunohematology IVD Panel-Based Tests, 2025 (%) [Emergency and Acute Care Units, Hospital Laboratories, Independent and Reference Laboratories, Physician Offices]
  • Geographic Market Overview
    • Table 8-2: Immunohematology Panel-Based Tests, Geographic Markets, 2025-2030 ($ million) [Asia Pacific, Europe, North America, RoW]
    • Figure 8-3: Regional Summary - Immunohematology IVD Panels, 2020-2030 ($ million) [Asia Pacific, Europe, North America, RoW]

Chapter 9: Market Panel-Based IVD Testing Analysis

  • Total Market
    • Table 9-1: Total IVD Panel Market, by Segment, 2020-2030 ($ million) [Anatomic Pathology, Core Laboratory, Immunoassay, Immunohematology, Molecular, Point-of-Care]
    • Figure 9-1: Total Panel-Based IVD Testing Market-Respiratory/Non-Respiratory, 2020-2030 ($ million)
    • Figure 9-2: Total Global Panel-Based IVD Testing Market-Respiratory/Non-Respiratory-Revenue Distribution, 2025 (%)
    • Respiratory IVD Panel-Based Testing Market
      • Table 9-2: Total Respiratory IVD Panel Market, 2020-2030 ($ million) [Immunoassay, Molecular, Point-of-Care]
      • Figure 9-3: Total Respiratory IVD Panel Market, 2020-2030 ($ million) [Immunoassay, Molecular, Point-of-Care]
    • Non-Respiratory Panel-Based IVD Testing Market
      • Table 9-3: Total Non-Respiratory IVD Panel Market, 2020-2030 ($ million)
      • Figure 9-4: Total Non-Respiratory IVD Panel Market, 2020-2030 ($ million) [Anatomic Pathology, Core Lab, Immunoassay, Immunohematology, Molecular, POC]
  • Market by Target
    • Respiratory
      • Table 9-4: Respiratory IVD Panels, 2020-2030 ($ million)
      • Figure 9-5: Respiratory IVD Panels, 2020-2030 ($ million)
    • Infectious Disease (Non-Respiratory)
      • Table 9-5: Infectious Disease Non-Respiratory Panel-Based Tests, Overall Market, 2025-2030 ($ million)
    • Bloodstream/HAI/Sepsis
      • Table 9-6: Bloodstream/HAI/Sepsis IVD Panels, 2020-2030 ($ million)
      • Figure 9-6: Bloodstream/HAI/Sepsis IVD Panels, 2020-2030 ($ million)
    • Sexually Transmitted Infections
      • Table 9-7: Sexually Transmitted Infection (STI) IVD Panels, 2020-2030 ($ million)
      • Figure 9-7: Sexually Transmitted Infection (STI) IVD Panels, 2020-2030 ($ million)
    • Hepatitis
      • Table 9-8: Hepatitis IVD Panels, 2020-2030 ($ million)
      • Figure 9-8: Hepatitis IVD Panels, 2020-2030 ($ million)
    • Blood Bank Screening
      • Table 9-9: Blood Bank Screening IVD Panels, 2020-2030 ($ million)
      • Figure 9-9: Blood Bank Screening IVD Panels, 2020-2030 ($ million)
    • ToRCH
      • Table 9-10: ToRCH IVD Panels, 2020-2030 ($ million)
      • Figure 9-10: ToRCH IVD Panels, 2020-2030 ($ million)
    • Other (Non-Respiratory) IVD Panel Targets
      • Table 9-11: Other, Non-Respiratory IVD Panel Targets, 20205-2030 ($ million)
      • Table 9-12: Other, Non-Respiratory IVD Panel Targets, by Type, 2025, ($ million) [Allergy, Autoimmune, Blood Gases + Critical Care, Blood Grouping/Typing, Genetic + Prenatal Testing, General Chemistry, Hematology, Immunohistochemistry (IHC), Lipid (Cholesterol), Oncology, Thyroid, Tissue Typing, Toxicology/Drugs of Abuse, Urinalysis, Other]
      • Figure 9-11: Other, Non-Respiratory IVD Panel Targets, by Type, 2025, ($ million) [Allergy, Autoimmune, Blood Gases + Critical Care, Blood Grouping/Typing, Genetic + Prenatal Testing, General Chemistry, Hematology, Immunohistochemistry (IHC), Lipid (Cholesterol), Oncology, Thyroid, Tissue Typing, Toxicology/Drugs of Abuse, Urinalysis, Other]
  • Market by End-User Distribution
    • Figure 9-12: Total Global Panel-Based IVD Testing Market, By End User, 2020-2030 ($ million) [Emergency/UC, Hospital, Independent/Reference, OTC/Retail, Physician Office]
    • Figure 9-13: Total Panel-Based IVD Testing Market, By End User, Revenue Distribution, 2025 (%) [Emergency/UC, Hospital, Independent/Reference, OTC/Retail, Physician Office]
    • Hospital Lab
      • Table 9-13: Hospital Lab IVD Panel-Based Test Revenue, 2025-2030 ($ million)
    • Emergency (ER)/Urgent Care (UC)
      • Table 9-14: Emergency (ER)/Urgent Care (UC) IVD Panel-Based Test Revenue, 2025-2030 ($ million)
    • Independent/Reference Lab
      • Table 9-15: Independent/Reference Lab IVD Panel-Based Test Revenue, 2025-2030 ($ million)
    • Physician Office
      • Table 9-16: Physician Office IVD Panel-Based Test Revenue, 2025-2030 ($ million)
    • OTC/Retail/Others
      • Table 9-17: OTC/Retail/Other IVD Panel-Based Test Revenue, 2025-2030 ($ million)
  • Market by Region
    • Figure 9-14: Total Panel-Based IVD Testing Market, By Geographic Region, 2020-2030 ($ million) [Asia Pacific, Europe, North America, RoW]
    • Figure 9-15: Total Panel-Based IVD Testing Market, By Geographic Region, Revenue Distribution, 2025 (%) [Asia Pacific, Europe, North America, RoW]
    • North America
      • Table 9-18: North America - IVD Panel-Based Test Revenue, 2025-2030 ($ million)
      • Figure 9-16: North America - IVD Panel Market, 2020-2030 ($ million) [Anatomic Pathology, Core Lab, Immunoassay, Immunohematology, Molecular, POC]
    • Europe
      • Table 9-19: Europe - IVD Panel-Based Test Revenue, 2025-2030 ($ million)
      • Figure 9-17: Europe - IVD Panel Market, 2020-2030 ($ million) [Anatomic Pathology, Core Lab, Immunoassay, Immunohematology, Molecular, POC]
    • Asia Pacific
      • Table 9-20: Asia Pacific - IVD Panel-Based Test Revenue, 2025-2030 ($ million)
      • Figure 9-18: Asia Pacific - IVD Panel Market, 2020-2030 ($ million) [Anatomic Pathology, Core Lab, Immunoassay, Immunohematology, Molecular, POC]
    • RoW
      • Table 9-21: Rest of World - IVD Panel-Based Test Revenue, 2025-2030 ($ million)
      • Figure 9-19: Rest of World - IVD Panel Market, 2020-2030 ($ million) [Anatomic Pathology, Core Lab, Immunoassay, Immunohematology, Molecular, POC]